Change Language

Select Language

COVID-19
The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.

Doxorubicin Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027

Market Overview:

The global doxorubicin market size reached US$ 1.12 Billion in 2021. Looking forward, IMARC Group expects the market to reach a value of US$ 1.62 Billion by 2027, exhibiting a CAGR of 6.10% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.

Doxorubicin (DOX) is a generic medicine used in the process of chemotherapy for treating cancer. It is used as an injection solution or in lyophilized powder form to intravenously administer through peripherally inserted central line catheter (PICC) or central venous catheter (CVC). DOX is rapidly eliminated by enzymes and encounters hydrolytic degradation in plasma after intravenous administration. It is used to treat several types of cancer, including breast cancer, bladder cancer, Kaposi’s sarcoma, lymphoma, Wilms’ tumor, non-Hodgkin’s lymphoma, and acute lymphocytic leukemia.

Doxorubicin Market Trends:

The increasing prevalence of cancer is primarily driving the global doxorubicin market. This has resulted in the growing use of DOX in combination with other chemotherapeutic agents to treat a variety of carcinomas. Besides this, the rising demand for minimally invasive (MI) surgical procedures and the growing geriatric population who cannot undergo significant surgeries have led to the growing preference for DOX as part of the cancer treatment therapies. Governments of different countries are also implementing initiatives to support technological advancements in clinical oncology, including intravenous free therapy and digital microfluidics for on-chip biochemical analysis. They are also increasing awareness programs for the treatment of cancer. As a result, there has been a significant increase in the demand for DOX. Furthermore, researchers are spending a considerable amount on clinical trials to develop technologically advanced DOX formulations. Moreover, the growing number of mergers and acquisitions as well as partnerships for clinical trials with advanced forms of DOX is expected to create a positive outlook for the market in the coming years.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global doxorubicin market, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on application and distribution channel.

Breakup by Application:

  • Breast Cancer
  • Ovarian Cancer
  • Multiple Myeloma
  • Kaposi Sarcoma
  • Leukemia
  • Bone Sarcoma
  • Endometrial Cancer
  • Others
     

Breakup by Distribution Channel:

  • Hospital and Retail Pharmacies
  • Online Stores
  • Others
     

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa
     

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Accord Healthcare Ltd. (Intas Pharmaceuticals Limited), Baxter International Inc., Cadila Pharmaceuticals, Cipla Inc., Hikma Pharmaceuticals PLC, Meiji Holdings Co. Ltd., Novartis AG and Pfizer Inc.

Report Coverage:

Report Features Details
Base Year of the Analysis 2021
    Historical Period 2016-2021
Forecast Period 2022-2027
Units US$ Billion
Segment Coverage Application, Distribution Channel, Region
Region Covered  Asia Pacific, Europe, North America, Latin America, Middle East and Africa
Countries Covered United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
Companies Covered Accord Healthcare Ltd. (Intas Pharmaceuticals Limited), Baxter International Inc., Cadila Pharmaceuticals, Cipla Inc., Hikma Pharmaceuticals PLC, Meiji Holdings Co. Ltd., Novartis AG and Pfizer Inc.
Customization Scope 10% Free Customization
Report Price and Purchase Option Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
Post-Sale Analyst Support 10-12 Weeks
Delivery Format PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

 

Key Questions Answered in This Report:

  • How has the global doxorubicin market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global doxorubicin market?
  • What are the key regional markets?
  • What is the breakup of the market based on the application?
  • What is the breakup of the market based on the distribution channel?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global doxorubicin market and who are the key players?
  • What is the degree of competition in the industry?

1    Preface
2    Scope and Methodology

    2.1    Objectives of the Study
    2.2    Stakeholders
    2.3    Data Sources
        2.3.1    Primary Sources
        2.3.2    Secondary Sources
    2.4    Market Estimation
        2.4.1    Bottom-Up Approach
        2.4.2    Top-Down Approach
    2.5    Forecasting Methodology
3    Executive Summary
4    Introduction

    4.1    Overview
    4.2    Key Industry Trends
5    Global Doxorubicin Market
    5.1    Market Overview
    5.2    Market Performance
    5.3    Impact of COVID-19
    5.4    Market Forecast
6    Market Breakup by Application
    6.1    Breast Cancer
        6.1.1 Market Trends
        6.1.2 Market Forecast
    6.2    Ovarian Cancer
        6.2.1 Market Trends
        6.2.2 Market Forecast
    6.3    Multiple Myeloma
        6.3.1 Market Trends
        6.3.2 Market Forecast
    6.4    Kaposi Sarcoma
        6.4.1 Market Trends
        6.4.2 Market Forecast
    6.5    Leukemia
        6.5.1 Market Trends
        6.5.2 Market Forecast
    6.6    Bone Sarcoma
        6.6.1 Market Trends
        6.6.2 Market Forecast
    6.7    Endometrial Cancer
        6.7.1 Market Trends
        6.7.2 Market Forecast
    6.8    Others
        6.8.1 Market Trends
        6.8.2 Market Forecast 
7    Market Breakup by Distribution Channel
    7.1    Hospital and Retail Pharmacies
        7.1.1 Market Trends
        7.1.2 Market Forecast
    7.2    Online Stores
        7.2.1 Market Trends
        7.2.2 Market Forecast
    7.3    Others
        7.3.1 Market Trends
        7.3.2 Market Forecast
8    Market Breakup by Region
    8.1    North America
        8.1.1 United States
           8.1.1.1 Market Trends
           8.1.1.2 Market Forecast
        8.1.2 Canada
           8.1.2.1 Market Trends
           8.1.2.2 Market Forecast
    8.2    Asia-Pacific
        8.2.1 China
           8.2.1.1 Market Trends
           8.2.1.2 Market Forecast
        8.2.2 Japan
           8.2.2.1 Market Trends
           8.2.2.2 Market Forecast
        8.2.3 India
           8.2.3.1 Market Trends
           8.2.3.2 Market Forecast
        8.2.4 South Korea
           8.2.4.1 Market Trends
           8.2.4.2 Market Forecast
        8.2.5 Australia
           8.2.5.1 Market Trends
           8.2.5.2 Market Forecast
        8.2.6 Indonesia
           8.2.6.1 Market Trends
           8.2.6.2 Market Forecast
        8.2.7 Others
           8.2.7.1 Market Trends
           8.2.7.2 Market Forecast
    8.3    Europe
        8.3.1 Germany
           8.3.1.1 Market Trends
           8.3.1.2 Market Forecast
        8.3.2 France
           8.3.2.1 Market Trends
           8.3.2.2 Market Forecast
        8.3.3 United Kingdom
           8.3.3.1 Market Trends
           8.3.3.2 Market Forecast
        8.3.4 Italy
           8.3.4.1 Market Trends
           8.3.4.2 Market Forecast
        8.3.5 Spain
           8.3.5.1 Market Trends
           8.3.5.2 Market Forecast
        8.3.6 Russia
           8.3.6.1 Market Trends
           8.3.6.2 Market Forecast
        8.3.7 Others
           8.3.7.1 Market Trends
           8.3.7.2 Market Forecast
    8.4    Latin America
        8.4.1 Brazil
           8.4.1.1 Market Trends
           8.4.1.2 Market Forecast
        8.4.2 Mexico
           8.4.2.1 Market Trends
           8.4.2.2 Market Forecast
        8.4.3 Others
           8.4.3.1 Market Trends
           8.4.3.2 Market Forecast
    8.5    Middle East and Africa
        8.5.1 Market Trends
        8.5.2 Market Breakup by Country
        8.5.3 Market Forecast
9    SWOT Analysis
    9.1    Overview
    9.2    Strengths
    9.3    Weaknesses
    9.4    Opportunities
    9.5    Threats
10    Value Chain Analysis
11    Porters Five Forces Analysis

    11.1    Overview
    11.2    Bargaining Power of Buyers
    11.3    Bargaining Power of Suppliers
    11.4    Degree of Competition
    11.5    Threat of New Entrants
    11.6    Threat of Substitutes
12    Price Analysis
13    Competitive Landscape

    13.1    Market Structure
    13.2    Key Players
    13.3    Profiles of Key Players
        13.3.1    Accord Healthcare Ltd. (Intas Pharmaceuticals Limited)
           13.3.1.1 Company Overview
           13.3.1.2 Product Portfolio
        13.3.2    Baxter International Inc.
           13.3.2.1 Company Overview
           13.3.2.2 Product Portfolio
           13.3.2.3 Financials
           13.3.2.4 SWOT Analysis
        13.3.3    Cadila Pharmaceuticals
           13.3.3.1 Company Overview
           13.3.3.2 Product Portfolio
        13.3.4    Cipla Inc.
           13.3.4.1 Company Overview
           13.3.4.2 Product Portfolio
           13.3.4.3 Financials
           13.3.4.4 SWOT Analysis
        13.3.5    Hikma Pharmaceuticals PLC
           13.3.5.1 Company Overview
           13.3.5.2 Product Portfolio
        13.3.6    Meiji Holdings Co. Ltd.
           13.3.6.1 Company Overview
           13.3.6.2 Product Portfolio
           13.3.6.3 Financials
           13.3.6.4 SWOT Analysis
        13.3.7    Novartis AG
           13.3.7.1 Company Overview
           13.3.7.2 Product Portfolio
           13.3.7.3 Financials
           13.3.7.4 SWOT Analysis
        13.3.8    Pfizer Inc.
           13.3.8.1 Company Overview
           13.3.8.2 Product Portfolio
           13.3.8.3 Financials
           13.3.8.4 SWOT Analysis 

List of Figures

Figure 1: Global: Doxorubicin Market: Major Drivers and Challenges
Figure 2: Global: Doxorubicin Market: Sales Value (in Billion US$), 2016-2021
Figure 3: Global: Doxorubicin Market Forecast: Sales Value (in Billion US$), 2022-2027
Figure 4: Global: Doxorubicin Market: Breakup by Application (in %), 2021
Figure 5: Global: Doxorubicin Market: Breakup by Distribution Channel (in %), 2021
Figure 6: Global: Doxorubicin Market: Breakup by Region (in %), 2021
Figure 7: Global: Doxorubicin (Breast Cancer) Market: Sales Value (in Million US$), 2016 & 2021
Figure 8: Global: Doxorubicin (Breast Cancer) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 9: Global: Doxorubicin (Ovarian Cancer) Market: Sales Value (in Million US$), 2016 & 2021
Figure 10: Global: Doxorubicin (Ovarian Cancer) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 11: Global: Doxorubicin (Multiple Myeloma) Market: Sales Value (in Million US$), 2016 & 2021
Figure 12: Global: Doxorubicin (Multiple Myeloma) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 13: Global: Doxorubicin (Kaposi Sarcoma) Market: Sales Value (in Million US$), 2016 & 2021
Figure 14: Global: Doxorubicin (Kaposi Sarcoma) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 15: Global: Doxorubicin (Leukemia) Market: Sales Value (in Million US$), 2016 & 2021
Figure 16: Global: Doxorubicin (Leukemia) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 17: Global: Doxorubicin (Bone Sarcoma) Market: Sales Value (in Million US$), 2016 & 2021
Figure 18: Global: Doxorubicin (Bone Sarcoma) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 19: Global: Doxorubicin (Endometrial Cancer) Market: Sales Value (in Million US$), 2016 & 2021
Figure 20: Global: Doxorubicin (Endometrial Cancer) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 21: Global: Doxorubicin (Other Applications) Market: Sales Value (in Million US$), 2016 & 2021
Figure 22: Global: Doxorubicin (Other Applications) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 23: Global: Doxorubicin (Hospital and Retail Pharmacies) Market: Sales Value (in Million US$), 2016 & 2021
Figure 24: Global: Doxorubicin (Hospital and Retail Pharmacies) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 25: Global: Doxorubicin (Online Stores) Market: Sales Value (in Million US$), 2016 & 2021
Figure 26: Global: Doxorubicin (Online Stores) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 27: Global: Doxorubicin (Other Distribution Channels) Market: Sales Value (in Million US$), 2016 & 2021
Figure 28: Global: Doxorubicin (Other Distribution Channels) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 29: North America: Doxorubicin Market: Sales Value (in Million US$), 2016 & 2021
Figure 30: North America: Doxorubicin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 31: United States: Doxorubicin Market: Sales Value (in Million US$), 2016 & 2021
Figure 32: United States: Doxorubicin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 33: Canada: Doxorubicin Market: Sales Value (in Million US$), 2016 & 2021
Figure 34: Canada: Doxorubicin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 35: Asia-Pacific: Doxorubicin Market: Sales Value (in Million US$), 2016 & 2021
Figure 36: Asia-Pacific: Doxorubicin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 37: China: Doxorubicin Market: Sales Value (in Million US$), 2016 & 2021
Figure 38: China: Doxorubicin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 39: Japan: Doxorubicin Market: Sales Value (in Million US$), 2016 & 2021
Figure 40: Japan: Doxorubicin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 41: India: Doxorubicin Market: Sales Value (in Million US$), 2016 & 2021
Figure 42: India: Doxorubicin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 43: South Korea: Doxorubicin Market: Sales Value (in Million US$), 2016 & 2021
Figure 44: South Korea: Doxorubicin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 45: Australia: Doxorubicin Market: Sales Value (in Million US$), 2016 & 2021
Figure 46: Australia: Doxorubicin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 47: Indonesia: Doxorubicin Market: Sales Value (in Million US$), 2016 & 2021
Figure 48: Indonesia: Doxorubicin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 49: Others: Doxorubicin Market: Sales Value (in Million US$), 2016 & 2021
Figure 50: Others: Doxorubicin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 51: Europe: Doxorubicin Market: Sales Value (in Million US$), 2016 & 2021
Figure 52: Europe: Doxorubicin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 53: Germany: Doxorubicin Market: Sales Value (in Million US$), 2016 & 2021
Figure 54: Germany: Doxorubicin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 55: France: Doxorubicin Market: Sales Value (in Million US$), 2016 & 2021
Figure 56: France: Doxorubicin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 57: United Kingdom: Doxorubicin Market: Sales Value (in Million US$), 2016 & 2021
Figure 58: United Kingdom: Doxorubicin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 59: Italy: Doxorubicin Market: Sales Value (in Million US$), 2016 & 2021
Figure 60: Italy: Doxorubicin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 61: Spain: Doxorubicin Market: Sales Value (in Million US$), 2016 & 2021
Figure 62: Spain: Doxorubicin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 63: Russia: Doxorubicin Market: Sales Value (in Million US$), 2016 & 2021
Figure 64: Russia: Doxorubicin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 65: Others: Doxorubicin Market: Sales Value (in Million US$), 2016 & 2021
Figure 66: Others: Doxorubicin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 67: Latin America: Doxorubicin Market: Sales Value (in Million US$), 2016 & 2021
Figure 68: Latin America: Doxorubicin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 69: Brazil: Doxorubicin Market: Sales Value (in Million US$), 2016 & 2021
Figure 70: Brazil: Doxorubicin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 71: Mexico: Doxorubicin Market: Sales Value (in Million US$), 2016 & 2021
Figure 72: Mexico: Doxorubicin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 73: Others: Doxorubicin Market: Sales Value (in Million US$), 2016 & 2021
Figure 74: Others: Doxorubicin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 75: Middle East and Africa: Doxorubicin Market: Sales Value (in Million US$), 2016 & 2021
Figure 76: Middle East and Africa: Doxorubicin Market: Breakup by Country (in %), 2021
Figure 77: Middle East and Africa: Doxorubicin Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 78: Global: Doxorubicin Industry: SWOT Analysis
Figure 79: Global: Doxorubicin Industry: Value Chain Analysis
Figure 80: Global: Doxorubicin Industry: Porter's Five Forces Analysis

List of Tables

Table 1: Global: Doxorubicin Market: Key Industry Highlights, 2021 and 2027
Table 2: Global: Doxorubicin Market Forecast: Breakup by Application (in Million US$), 2022-2027
Table 3: Global: Doxorubicin Market Forecast: Breakup by Distribution Channel (in Million US$), 2022-2027
Table 4: Global: Doxorubicin Market Forecast: Breakup by Region (in Million US$), 2022-2027
Table 5: Global: Doxorubicin Market: Competitive Structure
Table 6: Global: Doxorubicin Market: Key Players


Note: We value your privacy and will never rent or sell your email address. Privacy policy

Need more help?

  •   Speak to our experienced analysts for insights on the current market scenarios.
  •   Include additional segments and countries to customize the report as per your requirement.
  •   Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  •   For further assistance, please connect with our analysts.

Purchase Options




$ 2499

REACH OUT TO US

Call us on

( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )


Drop us an email at

sales@imarcgroup.com

Social Links

4